Eculizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Eculizumab: From Complement-Mediated Diseases (PNH, aHUS) to Cyclic Hematopoiesis
One-Sentence Summary
Eculizumab is a C5 complement inhibitor, used for complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and myasthenia gravis. The TxGNN model predicts it may be effective for cyclic hematopoiesis (cyclic neutropenia), but there are 0 clinical trials and 0 publications for this indication, so this is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | PNH, aHUS and myasthenia gravis (inferred from the drug’s literature, because the approved-indication text in the US license records is blank) |
| Predicted New Indication | Cyclic hematopoiesis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 (all BLAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in DrugBank for this record. Eculizumab is known to be a monoclonal antibody that inhibits complement component C5, blocking terminal complement activation. This is the basis of its use in PNH, aHUS and other complement-driven diseases.
The mechanistic link to the predicted indication is weak. Cyclic neutropenia is driven by ELANE mutations affecting neutrophil production and is not complement-mediated. The same problem applies to the other nine predictions, which are mostly neutropenia subtypes (JAGN1, WAS, CXCR2 and CSF3R defects, and idiopathic or severe congenital neutropenia). None has a known complement component. The cluster suggests the model is propagating from a disease-class neighborhood in the knowledge graph rather than from a drug-specific mechanism. The high score should therefore be read as a hypothesis-generation signal, not as support for efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Some lower-ranked predictions (for example, congenital neutropenia-myelofibrosis-nephromegaly syndrome) returned literature hits. All of these papers concern eculizumab’s established uses (PNH, aHUS/TMA, myasthenia gravis, CD59 deficiency). They do not address neutropenia, so they are drug-keyword matches and not disease evidence.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| BLA125166 | SOLIRIS | Injection, solution, concentrate | Alexion Pharmaceuticals Inc. |
| BLA761333 | BKEMV | Injection, solution, concentrate | Amgen Inc |
| BLA761340 | EPYSQLI | Injection, solution | Teva Pharmaceuticals USA, Inc. |
All three products are injectables. The source data does not include approved-indication text.
Safety Considerations
- Infection risk: Terminal complement blockade raises the risk of serious meningococcal infection. This is a particular concern in neutropenic or immunodeficient patients, which is the population targeted by all ten predicted indications.
- Drug interactions: No interactions were found in the DDI query.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score (L5). There are no trials or disease-specific publications, and there is no plausible complement-mediated mechanism in cyclic neutropenia. Adding C5 blockade to neutropenic patients would also add serious infection risk.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism-of-action data from DrugBank
- Preclinical or genetic evidence that complement activation contributes to cyclic neutropenia
- A benefit-risk assessment of meningococcal infection in neutropenic patients
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.